Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto-immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

Abstract: The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a —S(?O)(?N—)- functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient and a method for producing the fraction. More particularly, the present invention relates to a composition for preventing and treating inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, in which the extract of Trachelospermi caulis is refined and concentrated to contain 0.05˜12% by weight of arctigenin as an index material, and a method for producing the fraction.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient and a method for producing the fraction. More particularly, the present invention relates to a composition for preventing and treating inflammatory diseases comprising an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, in which the extract of Trachelospermi caulis is refined and concentrated to contain 0.05˜12% by weight of arctigenin as an index material, and a method for producing the fraction.